Sanofi ADR [NASDAQ: SNY] plunged by -$0.01 during the normal trading session on while it closed the day at $49.88. The company report on January 25, 2024 at 2:30 PM that Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE).
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo.
Sanofi ADR stock has also loss -3.86% of its value over the past 7 days. However, SNY stock has declined by -4.68% in the 3 months of the year. Over the past six months meanwhile, it has lost -6.78% and gained 0.30% year-on date.
The market cap for SNY stock reached $125.09 billion, with 2.51 billion shares outstanding and 2.51 billion shares in the current float. Compared to the average trading volume of 2.03M shares, SNY reached a trading volume of 2873492 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sanofi ADR [SNY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNY shares is $56.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNY stock is a recommendation set at 1.77. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Sanofi ADR shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on January 23, 2024.
The Average True Range (ATR) for Sanofi ADR is set at 0.75, with the Price to Sales ratio for SNY stock in the period of the last 12 months amounting to 2.76. The Price to Book ratio for the last quarter was 1.58, with the Price to Cash per share for the same quarter was set at 3.48. Price to Free Cash Flow for SNY in the course of the last twelve months was 15.32 with Quick ratio for the last quarter at 0.81.
SNY stock trade performance evaluation
Sanofi ADR [SNY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.86. With this latest performance, SNY shares gained by 2.34% in over the last four-week period, additionally sinking by -6.78% over the last 6 months – not to mention a rise of 2.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNY stock in for the last two-week period is set at 46.45, with the RSI for the last a single of trading hit 37.45, and the three-weeks RSI is set at 49.67 for Sanofi ADR [SNY]. The present Moving Average for the last 50 days of trading for this stock 48.67, while it was recorded at 50.30 for the last single week of trading, and 51.86 for the last 200 days.
Sanofi ADR [SNY]: An insightful look at the core fundamentals
Sanofi ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.81 and a Current Ratio set at 1.21.
Earnings per share (EPS) analysis for Sanofi ADR [SNY] stock
With the latest financial reports released by the company, Sanofi ADR posted 0.87/share EPS, while the average EPS was predicted by analysts to be reported at 0.9/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sanofi ADR go to 4.98%.
Sanofi ADR [SNY]: Institutional Ownership
The top three institutional holders of SNY stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in SNY stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in SNY stock with ownership which is approximately 5.8325%.
